在体和体外评估新型小分子抑制剂,以向乳腺癌细胞的亡途径
Piyush Kumar1, Blessing Wisdom Ike2, Raman Rajesh Kumar3
1JSS College of Pharmacy, Najwal, Vijaypur, Jammu, India.
Asian Pacific journal of cancer prevention : APJCP
|November 28, 2025
概括
新的小分子C12和C18通过诱导亡,显示出强大的抗乳腺癌活性. 这些化合物准关键信号通路,并表现出有利的药理动力学特性,表明治疗潜力.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 计算化学的计算化学
背景情况:
- 乳腺癌仍然是全球主要的死亡原因.
- 抑制癌细胞生存途径的向疗法正在推进治疗.
- 新型小分子对于开发更有效的乳腺癌疗法至关重要.
研究的目的:
- 设计和识别针对乳腺癌关键信号通路的小分子抑制剂.
- 在体外评估潜在候选药物的细胞毒性和亡效应.
- 预测已识别的化合物的药理动力学特性.
主要方法:
- 计算方法包括虚拟选和分子对接.
- 使用MCF7乳腺癌细胞进行细胞毒性 (IC50) 和亡的体外评估.
- 用于药理动力学评估的ADMET分析.
主要成果:
- 两个化合物,C12和C18,显示强烈的结合到氨酸-氨酸蛋白激酶和MAP3K5.5.
- 观察到显著的细胞毒性作用,IC50值为22.49微克/毫升 (C12) 和14.61微克/毫升 (C18).
- 通过核凝结,DNA碎片化和线粒体膜潜在损失确认了亡;预测了有利的ADMET概况.
结论:
- 化合物C12和C18对乳腺癌细胞表现出强烈的细胞毒性和前性活性.
- 这些化合物代表了对乳腺癌有前途的新型治疗药物.
- 需要进一步的体内研究来确认疗效和安全性.
更多相关视频
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
11.8K
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
19.1K
相关概念视频
The Intrinsic Apoptotic Pathway
8.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.2K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
